002550 千红制药
已收盘 05-15 15:00:00
资讯
新帖
简况
千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%
证券之星 · 05-14
千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%
股市必读：千红制药（002550）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：千红制药（002550）5月8日董秘有最新回复
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
证券之星 · 05-08
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 05-08
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
东海证券：给予千红制药买入评级
证券之星 · 05-08
东海证券：给予千红制药买入评级
千红制药（002550）披露2025年度报告网上说明会公告，5月6日股价上涨2.71%
证券之星 · 05-06
千红制药（002550）披露2025年度报告网上说明会公告，5月6日股价上涨2.71%
千红制药：公司不存在应披露而未披露的重大事项
证券之星 · 05-06
千红制药：公司不存在应披露而未披露的重大事项
股市必读：千红制药（002550）4月29日董秘有最新回复
证券之星 · 04-30
股市必读：千红制药（002550）4月29日董秘有最新回复
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
千红制药：公司可转债项目尚处于有序推进过程中
证券之星 · 04-27
千红制药：公司可转债项目尚处于有序推进过程中
股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%
证券之星 · 04-27
股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%
千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%
证券之星 · 04-24
千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%
千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%
智通财经 · 04-23
千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-23
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-20
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-17
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
千红制药：公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中
证券之星 · 04-14
千红制药：公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
证券之星 · 04-10
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
证券之星 · 04-09
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
千红制药：河南千牧项目已按计划于2025年7月正式投产并稳定运行
证券之星 · 04-01
千红制药：河南千牧项目已按计划于2025年7月正式投产并稳定运行
公司概况
公司名称：
常州千红生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-02-18
主营业务：
常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。
发行价格：
32.00
{"stockData":{"symbol":"002550","market":"SZ","secType":"STK","nameCN":"千红制药","latestPrice":6.92,"timestamp":1778828598000,"preClose":6.97,"halted":0,"volume":11904900,"delay":0,"changeRate":-0.0072,"floatShares":941000000,"shares":1280000000,"eps":0.2523,"marketStatus":"已收盘","change":-0.05,"latestTime":"05-15 15:00:00","open":6.97,"high":7,"low":6.87,"amount":82603100,"amplitude":0.0187,"askPrice":6.93,"askSize":609,"bidPrice":6.92,"bidSize":413,"shortable":0,"etf":0,"ttmEps":0.2523,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":6.97,"symbolType":"stock","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":7.67,"lowLimit":6.27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1279800000,"isCdr":false,"pbRate":3.13,"roa":"--","peRate":27.427665,"roe":"3.03%","epsLYR":0.32,"committee":-0.254798,"marketValue":8856000000,"turnoverRate":0.0126,"status":1,"floatMarketCap":6513000000},"requestUrl":"/m/hq/s/002550/wiki","defaultTab":"wiki","newsList":[{"id":"2635746638","title":"千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746638","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635746638?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:47","pubTimestamp":1778770030,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，千红制药报收于6.97元，较前一交易日下跌1.13%，最新总市值为89.2亿元。该股当日开盘7.09元，最高7.09元，最低6.96元，成交额达8452.93万元，换手率为1.28%。近日，千红制药发布《2025年度股东会决议公告》。公告显示，公司于2026年5月14日召开2025年度股东会，会议由董事会召集，董事长王耀方主持，采用现场与网络投票相结合方式召开。出席会议的股东及授权代表共513名，代表有表决权股份总数的41.1970%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426396","title":"股市必读：千红制药（002550）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634426396?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:48","pubTimestamp":1778438894,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，千红制药报收于7.09元，下跌0.28%，换手率1.25%，成交量11.77万手，成交额8346.92万元。当日关注点来自交易信息汇总：5月8日主力资金净流出608.31万元，散户资金净流入720.8万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633106487","title":"千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2633106487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633106487?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:07","pubTimestamp":1778224034,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月08日在投资者关系平台上答复投资者关心的问题。为什么公司的信披那么不透明甚至隐瞒呢？公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800021282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633248729","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2633248729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633248729?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:04","pubTimestamp":1778223862,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问宁独董:公司在2025年中期报告关于106创新药进展的描述中明确写道该药已完成期临床，但现实是该药却要做期b的补充临床验证，这是不是夸大临床进度误导投资者？作为独立董事有没有尽职做到监督作用？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800021238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633101326","title":"东海证券：给予千红制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633101326?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:35","pubTimestamp":1778200535,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,付婷近期对千红制药进行研究并发布了研究报告《公司简评报告：业绩短期放缓，期待创新转型成果》，给予千红制药买入评级。河南千牧已正式投产，为公司提供充足的肝素上游原材料，湖北千红药用酶原料药基地已竣工，支撑胰激肽原酶、弹性蛋白酶等核心制剂规模化生产。QHRD211注射液是重组人生长激素，目前已完成II期临床患者入组。公司主营业务整体稳健，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800007569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633318317","title":"千红制药（002550）披露2025年度报告网上说明会公告，5月6日股价上涨2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633318317","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633318317?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:36","pubTimestamp":1778060183,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，千红制药报收于7.19元，较前一交易日上涨2.71%，最新总市值为92.02亿元。该股当日开盘7.01元，最高7.36元，最低7.01元，成交额达1.68亿元，换手率为2.47%。千红制药于近日披露《关于举行2025年度报告网上说明会的公告》。公告显示，公司将于2026年5月8日15:00-16:00在全景网平台举行2025年度报告网上说明会，采用网络远程方式召开。公司将对普遍关注的问题在说明会上予以回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600027681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633900560","title":"千红制药：公司不存在应披露而未披露的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2633900560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633900560?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:39","pubTimestamp":1778056751,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月06日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请问:现在公司有多少应报露但还没有披露的重要消息？千红制药回复：尊敬的投资者您好，根据公司最新公告及信息披露记录，公司目前不存在任何根据《深圳证券交易所股票上市规则》等有关规定应予以披露而未披露的重大事项。公司将持续严格遵守信息披露相关规定，确保信息发布的真实、准确、完整和公平。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600025055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631152151","title":"股市必读：千红制药（002550）4月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2631152151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631152151?lang=zh_cn&edition=full","pubTime":"2026-04-30 04:36","pubTimestamp":1777495010,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，千红制药报收于7.09元，下跌0.28%，换手率1.19%，成交量11.23万手，成交额7985.95万元。董秘最新回复投资者： 从2025年公司的发展治理报告看到公司和天目湖健康研究院、昔关瑞等机构成立联合实验室是不是真的？当日关注点来自交易信息汇总：4月29日主力资金净流出970.83万元，散户资金净流入888.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000012882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300723","06978","BK1161","002550","BK0209","BK0175","688621","BK0216","BK1574","BK0132","600216","BK0188","688117","LU1969619763.USD","000950","BK0071","BK0250","301281","BK0183","BK0187","BK0239","BK0028","LU2328871848.SGD","BK0196","BK0191","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630356449","title":"千红制药：公司可转债项目尚处于有序推进过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2630356449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630356449?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:33","pubTimestamp":1777260819,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药04月27日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司于2024年12月召开2024年第三次临时股东大会审议通过的可转债预案，已于2025年12月召开2025年第二次临时股东会审议通过了修订稿，公司可转债项目尚处于有序推进过程中，后续进展将依法及时公告，感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700017540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336937","title":"股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630336937?lang=zh_cn&edition=full","pubTime":"2026-04-27 03:27","pubTimestamp":1777231631,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告千红制药2025年年报显示，当年度公司主营收入15.71亿元，同比上升2.95%；归母净利润3.99亿元，同比上升12.01%；扣非净利润2.83亿元，同比上升5.33%；其中2025年第四季度，公司单季度主营收入3.56亿元，同比上升11.81%；单季度归母净利润1556.93万元，同比下降66.48%；单季度扣非净利润1229.98万元，同比下降69.83%；负债率10.43%，投资收益1159.24万元，财务费用480.94万元，毛利率58.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629127814","title":"千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629127814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629127814?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:36","pubTimestamp":1777023368,"startTime":"0","endTime":"0","summary":"证券之星消息，近日千红制药披露，截至2026年3月31日公司股东户数为7.45万户，较12月31日增加1768.0户，增幅为2.43%。在化学制药行业个股中，千红制药股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.51万户。从股价来看，2025年12月31日至2026年3月31日，千红制药区间跌幅为2.8%，在此期间股东户数增加1768.0户，增幅为2.43%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629557398","title":"千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629557398","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629557398?lang=zh_cn&edition=full","pubTime":"2026-04-23 23:33","pubTimestamp":1776958392,"startTime":"0","endTime":"0","summary":"智通财经APP讯，千红制药(002550.SZ)发布2026年第一季度报告，第一季度，公司实现营业收入3.58亿元，同比下降20.58%。归属于上市公司股东的净利润8505.51万元，同比下降47.16%。归属于上市公司股东的扣除非经常性损益的净利润7740.74万元，同比下降27.60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629100079","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2629100079","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629100079?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:06","pubTimestamp":1776927979,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘:为什么你在前期回复公司的创新药106项目的临床进度，说法和监管部门窗口实际批准公布临床存前后不一、自相矛盾？是否涉嫌故意误导投资者？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300037287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628717097","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2628717097","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628717097?lang=zh_cn&edition=full","pubTime":"2026-04-20 15:36","pubTimestamp":1776670567,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘:你以前在互动易提问回复中说106创新药正在和CDE沟通申请进行三期临床试验，那么在长达一年的时间里开了几次沟通会议、有没有沟通记录和监管部门给出了什么切实可行建议？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000015018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628226228","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2628226228","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628226228?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:42","pubTimestamp":1776386529,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药04月16日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700009972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627241833","title":"千红制药：公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2627241833","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627241833?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:04","pubTimestamp":1776150256,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：为什么公司的创新药106二期临床补充验证迟迟没有开展？是否属于事实上夭折失败项目？千红制药回复：尊敬的投资者，您好，公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规要求披露。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400018641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626607981","title":"千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626607981","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626607981?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:24","pubTimestamp":1775809452,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的106要进行b的临床，但是董秘却在互动中回复说和监管部门沟通期临床，请问这是不是刻意误导行为？千红制药回复：尊敬的投资者，您好，公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000027292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","BK1161","159992","BK1574","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626909694","title":"千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2626909694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626909694?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:03","pubTimestamp":1775718191,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你长期选择性发布公告，公司是不是存在严重的问题？千红制药回复：尊敬的投资者，您好，公司严格按照证监会和交易所的相关规定履行信息披露义务，不存在应披露未披露的重大事项。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900018613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624644975","title":"千红制药：河南千牧项目已按计划于2025年7月正式投产并稳定运行","url":"https://stock-news.laohu8.com/highlight/detail?id=2624644975","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624644975?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:34","pubTimestamp":1775014475,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药03月31日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，关注到河南千牧项目粗品线已于2025年6月投产并稳定运行，请问目前原料药车间的建设进度如何？计划是分步进行还是同步推进？千红制药回复：尊敬的投资者，您好，河南千牧项目已按计划于2025年7月正式投产并稳定运行，公司将严格按照GMP标准并遵循相关法规要求有序推进后续工作，力争早日实现产业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100018459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779042881482,"stockEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.1372},{"period":"3month","weight":-0.1036},{"period":"6month","weight":-0.2486},{"period":"1year","weight":0.1807},{"period":"ytd","weight":-0.1196}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"常州千红生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"74524人(较上一季度增加2.43%)","perCapita":"12630股","listingDate":"2011-02-18","address":"江苏省常州市新北区云河路518号","registeredCapital":"127980万元","survey":" 常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。","listedPrice":32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千红制药,002550,千红制药股票,千红制药股票老虎,千红制药股票老虎国际,千红制药行情,千红制药股票行情,千红制药股价,千红制药股市,千红制药股票价格,千红制药股票交易,千红制药股票购买,千红制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}